Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Current Assets (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Current Assets for 6 consecutive years, with $45.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 39.78% to $45.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.0 million through Dec 2025, down 39.78% year-over-year, with the annual reading at $45.0 million for FY2025, 39.78% down from the prior year.
  • Current Assets for Q4 2025 was $45.0 million at Mereo BioPharma, down from $52.4 million in the prior quarter.
  • The five-year high for Current Assets was $133.9 million in Q4 2021, with the low at $45.0 million in Q4 2025.
  • Average Current Assets over 5 years is $73.4 million, with a median of $66.9 million recorded in 2025.
  • The sharpest move saw Current Assets skyrocketed 241.1% in 2021, then crashed 43.84% in 2022.
  • Over 5 years, Current Assets stood at $133.9 million in 2021, then plummeted by 43.84% to $75.2 million in 2022, then decreased by 15.21% to $63.8 million in 2023, then rose by 17.26% to $74.8 million in 2024, then crashed by 39.78% to $45.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $45.0 million, $52.4 million, and $61.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.